# DexCom Shares Rise as Journal Study Supports Medicare Coverage for G7 Device

- URL: https://stocks.freetheai.org/news/dexcom-shares-rise-as-journal-study-supports-medicare-coverage-for-g7-device-b1396c
- Published: 2026-10-15T14:04:41Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:DXCM](https://stocks.freetheai.org/symbols/NASDAQ-DXCM)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

DexCom, Inc. (NASDAQ:DXCM) shares gained 4.41% to $87.15 on Thursday following the publication of positive clinical trial data in The New England Journal of Medicine. The study evaluated the company's G7 continuous glucose monitoring system in adults living with type 2 diabetes who do not take insulin.

Results from the 440-patient CONNECT trial, conducted across 22 U.S. primary care locations, demonstrated that non-insulin type 2 diabetes patients using the G7 device reduced their A1C levels by an average of 1.6% from baseline. This represented a 0.9% greater reduction compared to standard care. Additionally, users spent approximately five more hours per day within the targeted glucose range of 70 to 180 mg/dL. The peer-reviewed findings strengthen the clinical evidence needed to secure Medicare coverage for this patient segment.

Wall Street analysts expect a Medicare coverage determination before the end of 2026, with full reimbursement implementation potentially following by mid-2027. Broader coverage could significantly expand the addressable market for DexCom's glucose monitoring technology among non-insulin-dependent diabetes patients.

## Key points

- DexCom, Inc. (NASDAQ:DXCM) stock rose 4.41% to $87.15 following published trial results for its G7 monitor.
- The New England Journal of Medicine published findings from the 440-patient CONNECT study in non-insulin type 2 diabetes adults.
- Patients using the G7 device achieved an average 1.6% A1C reduction and spent 5 extra hours daily in target glucose range.
- The trial results strengthen the case for Medicare reimbursement coverage for non-insulin type 2 diabetes patients.
- A Medicare coverage decision is anticipated before year-end 2026, with target implementation in mid-2027.

## Questions and answers

### Why did DexCom stock go up today?

DexCom shares rose after clinical trial results published in The New England Journal of Medicine showed its G7 continuous glucose monitor significantly improved A1C levels in non-insulin type 2 diabetes patients, boosting prospects for Medicare coverage.

### What were the results of the DexCom CONNECT trial?

The trial found that non-insulin type 2 diabetes patients using the G7 device reduced A1C by an average of 1.6%—0.9% better than routine care—and gained roughly five additional hours per day in target glucose range.

### When could Medicare cover DexCom G7 for non-insulin type 2 diabetes?

A Medicare reimbursement decision is expected before the end of 2026, with potential coverage implementation occurring by mid-2027.